Extraglandular Manifestations of Sjögren's Syndrome
All five listed conditions—chronic pancreatitis, autoimmune hepatitis, cutaneous vasculitis, multiple myeloma, and peripheral neuropathy—are recognized extraglandular manifestations of Sjögren's syndrome, though they vary significantly in frequency and clinical importance.
Breakdown by Manifestation
Cutaneous Vasculitis (Option c)
This is one of the most common and clinically significant extraglandular manifestations. Vasculitis occurs in approximately 5-10% of Sjögren's syndrome patients and typically presents as palpable purpura with leukocytoclastic vasculitis on pathology 1, 2. Skin vasculitis is associated with more severe systemic disease and serves as a negative prognostic marker, particularly when accompanied by cryoglobulinemia and decreased complement levels 2. While half of patients experience only a single episode, its presence signals the need for closer monitoring and potential immunosuppressive therapy 1.
Peripheral Neuropathy (Option e)
Peripheral neuropathy represents the most frequent neurological complication, affecting up to 20% of Sjögren's syndrome patients 3, 4. The spectrum includes:
- Small fiber sensory neuropathy (most common type) presenting with painful dysesthesias, requiring skin biopsy showing reduced nerve fiber density for diagnosis 5
- Pure sensory neuropathy with distal symmetric sensory loss from axonal degeneration 5
- Sensory ataxic neuropathy (ganglionopathy) from proprioceptive fiber loss 5
- Sensorimotor polyneuropathy, often associated with severe systemic manifestations like cryoglobulinemia 5
- Rare variants including autonomic neuropathy and mononeuropathy multiplex 5
The heterogeneity of neuropathic presentations complicates diagnosis and requires targeted evaluation based on the specific clinical phenotype 3, 6.
Autoimmune Hepatitis (Option b)
Autoimmune hepatitis is a documented but less common extraglandular manifestation. A 2024 case report specifically describes concomitant IgA nephropathy and autoimmune hepatitis as initial manifestations of primary Sjögren's syndrome, with the patient being asymptomatic for liver involvement despite laboratory abnormalities 7. This underscores the importance of screening for hepatic involvement even in asymptomatic patients.
Chronic Pancreatitis (Option a)
While not extensively detailed in the provided evidence, pancreatic involvement is recognized as an extraglandular manifestation of Sjögren's syndrome. The disease can affect multiple organ systems through mononuclear infiltration and immune complex deposition 4.
Multiple Myeloma (Option d)
Sjögren's syndrome patients face increased risk of lymphoproliferative disorders, including progression to lymphoma in 2-5% of cases 8, 9. Monoclonal gammopathies are recognized manifestations 10. Patients with decreased C4 complement levels at diagnosis have higher lymphoma risk 9, 11. While multiple myeloma specifically is less commonly discussed than B-cell non-Hodgkin's lymphomas, the spectrum of plasma cell dyscrasias and monoclonal gammopathies encompasses this risk.
Clinical Implications
Key prognostic markers for severe extraglandular disease include:
- Cryoglobulinemia
- Hypocomplementemia (especially low C4)
- Vasculitic manifestations
- Monoclonal gammopathies 8, 2
Critical pitfall: Extraglandular manifestations may be the presenting features of Sjögren's syndrome, occurring before or without prominent sicca symptoms 12, 7. A 2025 case report documented a patient whose only presenting symptoms were extraglandular, affecting multiple organs and causing critical illness 12. This emphasizes the need for high clinical suspicion and thorough evaluation even when classic glandular symptoms are absent.
Management approach: All Sjögren's syndrome patients should be co-managed with rheumatology given the potential for multiple systemic complications 9, 11. Approximately 40% of patients develop extraglandular involvement 2, necessitating systematic screening for these manifestations to enable early intervention and prevent severe disability 3.